Is EGFR really a therapeutic target in head and neck cancers?
Antineoplastic Agents, Immunological
/ therapeutic use
Carcinoma, Squamous Cell
/ drug therapy
Cetuximab
/ therapeutic use
Chemotherapy, Adjuvant
Clinical Trials as Topic
ErbB Receptors
/ antagonists & inhibitors
Erlotinib Hydrochloride
/ therapeutic use
Gefitinib
/ therapeutic use
Head and Neck Neoplasms
/ drug therapy
Humans
Panitumumab
/ therapeutic use
Protein Kinase Inhibitors
/ therapeutic use
Radiotherapy, Adjuvant
Cetuximab
EGFR
concurrent chemotherapy
immunotherapy
targeted
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
07
12
2018
accepted:
14
01
2019
pubmed:
1
2
2019
medline:
18
4
2019
entrez:
1
2
2019
Statut:
ppublish
Résumé
Epidermal growth factor receptor (EGFR) is overexpressed in 90% to 100% of squamous cell carcinoma of the head and neck (SCCHN). The overexpression of EGFR and its ligand transforming growth factor is associated with poorer survival. EGFR inhibitors such as Cetuximab (Erbitux) have shown a significant antitumoral effect in SCCHN and has improved locoregional control and as well as survival. Even though there was some success with Cetuximab, work with other EGFR inhibition has not been very fruitful and not really shown any promise. Mechanism of action of Cetuximab could be immune-mediated rather than EGFR inhibition and EGFR may not necessarily be a therapeutic target in SCCHN.
Substances chimiques
Antineoplastic Agents, Immunological
0
Protein Kinase Inhibitors
0
Panitumumab
6A901E312A
Erlotinib Hydrochloride
DA87705X9K
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Cetuximab
PQX0D8J21J
Gefitinib
S65743JHBS
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
685-686Informations de copyright
© 2019 Wiley Periodicals, Inc.